The main objective of the GeneHumdi action is to bring together pharmaceutical companies, academic institutions, scientific and regulatory agencies, biotech companies, patient advocacy groups and information technologies to address the fragmentation of knowledge in order to accelerate the translation of genetic engineering technologies to the treatment of human diseases. GeneHumdi is supported by COST (European Cooperation in Science and Technology), a funding organisation for research and innovation networks operating in Europe since 1971. GeneHumdi draws on the exchange of ideas between members of the Management Committee (MC) from more than 24 EU countries, and the MC and other members organise themselves into Working Groups (WGs) to distribute GeneHumdi’s workload and assign specific issues to dedicated experts in each field.

Code: OC-2021-1-25175

Funding entity: Comisión Europea

Center: GENYO

Time of implementation: 01/01/2023 – 01/12/2024

Principal Investigator: Dr. Karim Benabdellah El Khlanji

More information: https://www.genehumdi.eu/

 

Other international projects